Moomoo AI 已提取核心訊息
On December 31, 2023, BlackRock, Inc., a Delaware-based investment management corporation, filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a 7.1% ownership stake in Novavax Inc., a biotechnology company specializing in vaccine development. The filing, which is the fourth amendment, shows that BlackRock has sole voting power over 8,323,116 shares and sole dispositive power over 8,436,179 shares of Novavax's common stock. This position by BlackRock does not aim to change or influence the control of Novavax. The filing was certified by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., on January 26, 2024.
On December 31, 2023, BlackRock, Inc., a Delaware-based investment management corporation, filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a 7.1% ownership stake in Novavax Inc., a biotechnology company specializing in vaccine development. The filing, which is the fourth amendment, shows that BlackRock has sole voting power over 8,323,116 shares and sole dispositive power over 8,436,179 shares of Novavax's common stock. This position by BlackRock does not aim to change or influence the control of Novavax. The filing was certified by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., on January 26, 2024.
2023年12月31日，總部位於特拉華州的投資管理公司貝萊德公司向美國證券交易委員會（SEC）提交了經修訂的附表13G，表示擁有專門從事疫苗開發的生物技術公司Novavax Inc. 7.1％的所有權。該文件是第四項修正案，顯示貝萊德對8,323,116股股票擁有唯一的投票權，對Novavax普通股的8,436,179股擁有唯一的處置權。貝萊德的這一立場並不是爲了改變或影響Novavax的控制權。該文件於2024年1月26日獲得貝萊德公司事實律師斯賓塞·弗萊明的認證。
2023年12月31日，總部位於特拉華州的投資管理公司貝萊德公司向美國證券交易委員會（SEC）提交了經修訂的附表13G，表示擁有專門從事疫苗開發的生物技術公司Novavax Inc. 7.1％的所有權。該文件是第四項修正案，顯示貝萊德對8,323,116股股票擁有唯一的投票權，對Novavax普通股的8,436,179股擁有唯一的處置權。貝萊德的這一立場並不是爲了改變或影響Novavax的控制權。該文件於2024年1月26日獲得貝萊德公司事實律師斯賓塞·弗萊明的認證。
有用
沒用